stockrow
Saturday 7 November 2026
Export ACHV’s income statement to Excel — free account
Achieve Life Sciences, Inc.
ACHV Healthcare Biotechnology
- EPS
- −116.2%
- Free cash flow
- −19.0%
- Total debt
- +63.9%
Quarter to June 2026, against a year earlier
6.73
0.35
+5.49%
Follow ACHV
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | 16 | — | 38 | 38 | 142 | +93.5% | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | (2) | (14) | (13) | (16) | (15) | (33) | (42) | (30) | (40) | (55) | (114) | +46.7% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (1) | (11) | (13) | (16) | (15) | (33) | (42) | (30) | (40) | (55) | (114) | +52.4% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (11,625.06) | (442.00) | (72.20) | (39.80) | (5.42) | (4.08) | (4.00) | (1.50) | (1.24) | (1.25) | (1.55) | (63.8%) | ||||||
| Cash flow | (2,020.00) | (379.46) | (60.53) | (36.93) | (4.96) | (3.63) | (3.55) | (1.23) | (0.93) | (1.13) | (0.50) | (56.5%) | ||||||
| Capex | 0.00 | 0.00 | (0.21) | (0.13) | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | (2,020.00) | (379.46) | (60.73) | (37.06) | (4.96) | (3.63) | (3.55) | (1.24) | (0.93) | (1.13) | (0.50) | (56.5%) | ||||||
| Book value | 6,100.00 | 328.29 | 90.04 | 43.81 | 13.71 | 3.45 | 0.78 | (0.07) | 0.65 | 0.49 | (0.16) | (64.9%) | ||||||
| Shares, m | 0 | 0 | 0 | 0 | 3 | 8 | 11 | 20 | 32 | 44 | 60 | +323.3% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 0.00 | — | — | — | — | — | — | — | — | — | 0.00 | — | |||||
| P/S | 0.01 | — | — | — | — | — | — | — | — | — | 39.77 | — | ||||||
| P/B | 0.18 | — | — | — | — | — | — | — | — | — | 0.00 | — | ||||||
| EV/Sales | 0.06 | — | — | — | — | — | — | — | — | — | 28.97 | — | ||||||
| EV/FCF | (1.85) | — | — | — | — | — | — | — | — | — | (9.74) | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | 0 | (9) | (11) | (15) | (13) | (29) | (38) | (24) | (30) | (49) | (47) | +84.3% | |||||
| Capex | 0 | — | 0 | 0 | 0 | — | — | 0 | — | 0 | 0 | (23.8%) | ||||||
| Free cash flow | 0 | (9) | (11) | (15) | (13) | (29) | (38) | (24) | (30) | (49) | (47) | +84.3% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | (3) | 4 | 12 | 14 | 34 | 40 | 6 | (4) | 30 | 31 | (9) | n/m | |||||
| Net debt | 1 | (5) | (15) | (16) | (36) | (28) | (9) | 1 | (24) | (20) | (171) | n/m | ||||||
| Shareholders’ equity | 1 | 8 | 16 | 18 | 37 | 28 | 8 | (1) | 21 | 22 | (15) | +48.6% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (3.98) | (154.51) | (87.57) | (81.64) | (48.00) | (75.51) | (109.31) | (120.85) | (137.33) | (135.90) | (91.46) | (131.9) pt | |||||
| ROIC | (75.23) | (172.71) | (655.87) | (590.96) | (575.45) | (159,105.77) | 0.00 | 0.00 | 0.00 | (2,109.47) | 0.00 | (2,034.2) pt | ||||||
| ROE | (6.49) | (249.33) | (107.15) | (96.86) | (53.24) | (101.49) | (233.04) | (869.88) | (409.51) | (257.67) | (844.99) | (251.2) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 17 | 13 | 13 | 14 | 13 | 16 | 20 | 22 | 25 | 28 | — | +5.7% | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2014 · latest quarter Jun 2016
Achieve Life Sciences, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ATTO Attovia Therapeutics, Inc. | $684.8M | — | — | — | n/m | — | 100.00% | (4,845.11%) | Compare |
| DNA Ginkgo Bioworks Holdings, Inc. | $670.7M | — (loss-making) | — (loss-making) | −59.37% (below 0%: shrinking) | n/m | −16.38% (below 0%: shrinking) | 91.47% | (290.47%) | Compare |
| SLDB Solid Biosciences Inc. | $662.7M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | −39.56% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| AURA Aura Biosciences, Inc. | $657.5M | — (loss-making) | — | — | n/m | −56.26% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ACHV Achieve Life Sciences, Inc. | $656.0M | — (loss-making) | — | +54.44% (above 0%: growing) | n/m | −19.01% (below 0%: shrinking) | 0.00% | 0.00% | |
| SGMT Sagimet Biosciences Inc. | $641.5M | — (loss-making) | — (loss-making) | — | n/m | −21.95% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| WVE WAVE Life Sciences Ltd. | $635.1M | — (loss-making) | — (loss-making) | +72.95% (above 0%: growing) | n/m | −33.94% (below 0%: shrinking) | 100.00% | (501.95%) | Compare |
| ZVRA Zevra Therapeutics, Inc. | $626.6M | 9.0× | 9.2× | +44.86% (above 0%: growing) | n/m | +106.77% (above 0%: growing) | 95.25% | 30.67% | Compare |
| FDMT 4D Molecular Therapeutics, Inc. | $621.5M | — (loss-making) | — (loss-making) | +25,106.67% (above 0%: growing) | n/m | −61.28% (below 0%: shrinking) | 100.00% | (2,037.16%) | Compare |
| Median of peers | $649.5M | — | — | +44.86% | — | −33.94% | 97.63% | (145.23%) |
Pay and ownership Proxy statement filed 8 June 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2024 | 2.52m | 2.20m | 143.67 |
| 2023 | 1.70m | 1.64m | 168.16 |
Ownership
Directors and executive officers, together
1.80%
venBio Global Strategic Fund V, L.P.
9.99%
Paradigm BioCapital International Fund Ltd.
9.65%
Franklin Resources, Inc.
8.08%
Frazier Life Sciences
7.27%
TPG LSI Rise Auriga L.P.
6.70%
Venrock Healthcare Capital Partners III, L.P.
5.36%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement